infigratinib

Infigratinib is an orally bioavailable, small molecule, pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. It selectively and reversibly binds to and inhibits FGFR1, FGFR2, FGFR3, and to a lesser extent FGFR4. By blocking these receptors—especially in tumors with activating mutations or rearrangements such as FGFR2 fusions—infigratinib suppresses downstream signaling pathways (RAS-MAPK and PI3K-AKT), leading to reduced tumor cell proliferation, angiogenesis inhibition, induction of apoptosis, and tumor cell death. Infigratinib was developed primarily for the treatment of previously treated unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring an FGFR2 fusion or other rearrangement[1][2][5][6][8]. The drug was co-developed by QED Therapeutics and Helsinn[5].

Brand names

Truseltiq

Other names

infigratinib